A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy

Adoptive T cell therapy (ACT) with genetically modified T cells has shown impressive results against some hematologic cancers, but efficacy in solid tumors can be limited by restrictive tumor microenvironments (TMEs). For example, Fas ligand is commonly overexpressed in TMEs and induces apoptosis in...

Full description

Saved in:

Bibliographic Details
Published in:	The Journal of experimental medicine Vol. 217; no. 12
Main Authors:	Oda, Shannon K, Anderson, Kristin G, Ravikumar, Pranali, Bonson, Patrick, Garcia, Nicolas M, Jenkins, Cody M, Zhuang, Summer, Daman, Andrew W, Chiu, Edison Y, Bates, Breanna M, Greenberg, Philip D
Format:	Journal Article
Language:	English
Published:	United States 07.12.2020
Subjects:	Animals Cell Death - drug effects Cell Engineering Cell Proliferation - drug effects Cell Survival - drug effects Cytokines - metabolism Disease Models, Animal fas Receptor - metabolism Humans Immunologic Factors - pharmacology Immunotherapy, Adoptive Leukemia - immunology Leukemia - pathology Leukemia - therapy Mice, Inbred C57BL Pancreatic Neoplasms - immunology Pancreatic Neoplasms - pathology Phenotype Recombinant Fusion Proteins - pharmacology Signal Transduction - drug effects T-Lymphocytes - drug effects T-Lymphocytes - immunology Tumor Necrosis Factor Receptor Superfamily, Member 9 - metabolism
ISSN:	1540-9538, 1540-9538
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!